patient subgroup...
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
favipiravir - versus control - for COVID 19 hospitalized
pdf
xlsx
method
abbreviations
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
efficacy endpoints 00 death D28 0.69 [0.28, 1.68]< 1 0% 1 study (1/-) 79.1 % NA not evaluable crucial - deaths 1.07 [0.62, 1.83]< 1 0% 6 studies (6/-) 40.4 % some concern not evaluable moderate crucial - clinical improvement 1.65 [1.28, 2.13]> 1 0% 5 studies (5/-) 100.0 % some concern not evaluable moderate important - clinical improvement (14-day) 1.26 [1.04, 1.53]> 1 0% 3 studies (3/-) 99.0 % some concern not evaluable moderate important - clinical improvement (28-day) 1.32 [0.86, 2.03]> 1 70% 2 studies (2/-) 89.4 % some concern not evaluable moderate important - clinical improvement (7-day) 1.62 [1.15, 2.28]> 1 0% 2 studies (2/-) 99.7 % some concern not evaluable moderate important - clinical improvement (time to event analysis only) 1.23 [0.93, 1.63]> 1 68% 5 studies (5/-) 92.9 % some concern not evaluable moderate important - hospital discharge 1.08 [0.85, 1.35]> 1 45% 3 studies (3/-) 73.2 % some concern not evaluable moderate important - hospitalization 0.12 [0.01, 2.26]< 1 0% 1 study (1/-) 92.0 % NA not evaluable important - mechanical ventilation 0.06 [0.01, 0.83]< 1 0% 1 study (1/-) 98.2 % NA not evaluable important - mechanical ventilation (time to event analysis only) 0.06 [0.01, 0.83]< 1 0% 1 study (1/-) 98.2 % NA not evaluable important - viral clearance 1.48 [0.94, 2.34]> 1 69% 7 studies (7/-) 95.5 % some concern not evaluable moderate important - viral clearance (time to event analysis only) 1.13 [0.82, 1.57]> 1 54% 3 studies (3/-) 77.1 % low not evaluable high important - viral clearance by day 14 1.12 [0.48, 2.63]> 1 32% 3 studies (3/-) 60.4 % some concern not evaluable moderate important - viral clearance by day 7 1.44 [0.78, 2.65]> 1 61% 3 studies (3/-) 87.5 % some concern not evaluable moderate important - ICU admission 1.48 [0.83, 2.64]< 1 0% 2 studies (2/-) 9.1 % some concern not evaluable moderate non important - safety endpoints 00 serious adverse events 2.73 [0.55, 13.60]< 1 0% 4 studies (4/-) 11.1 % some concern not evaluable moderate important - adverse events 3.33 [1.23, 9.02]< 1 87% 5 studies (5/-) 0.9 % some concern serious moderate non important -
LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias;
suggested: nominally statistically significant but without a strict control of overall risk of type 1 error;
inconclusive: not nominally statistically significant;
safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies;
published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE.
Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.